Generic Medicine Info
Indications and Dosage
Adult: 200-800 mg daily.

Adult: Initially, 200-400 mg bid, may increase to max of 1,200 mg bid in patients w/ mainly positive symptoms or up to a total of 800 mg daily in patients w/ mainly negative symptoms. Patients w/ mixed positive and negative symptoms (neither predominating): 400-600 mg bid.
Child: ≥14 yr Same as adult dose.
Elderly: Lower initial dose, adjust as required.
Renal Impairment
May require dosage reduction or longer dosage interval.
May be taken with or without food.
Phaeochromocytoma and acute porphyria; concomitant prolactin-dependent tumours (e.g. pituitary gland prolactinomas, breast cancer). Combination w/ levodopa.
Special Precautions
Patient w/ Parkinson's disease, epilepsy, CV disorders, stroke risk factors. Excited, agitated or aggressive patients. Avoid abrupt withdrawal. Renal impairment. Elderly w/ dementia-related psychosis. Pregnancy and lactation.
Adverse Reactions
Postural hypotension, hyperprolactinaemia, wt gain, increase in hepatic enzymes, sedation or drowsiness, insomnia, extrapyramidal symptoms, maculopapular rash, venous thromboembolism, pulmonary embolism, DVT, leucopenia, neutropenia, agranulocytosis.
Potentially Fatal: Neuroleptic malignant syndrome, QT prolongation and ventricular arrhythmias (e.g. torsades de pointes and ventricular tachycardia).
Patient Counseling Information
This drug may cause sedation, if affected, do not drive or operate machinery.
Symptoms: Restlessness, clouding of consciousness, extrapyramidal symptoms, agitation, confusion, low BP, coma. Management: Symptomatic and supportive treatment. May be partially removed by haemodialysis or treated w/ alkaline osmotic diuresis and anti-parkinsonian drugs, if necessary.
Drug Interactions
Combination w/ bradycardia-inducing medications (e.g. β-blockers, some Ca channel blockers) or medications which induce electrolyte imbalance (e.g. hypokalaemic diuretics, stimulant laxatives, IV amphotericin B, glucocorticoids, tetracosactides) may induce torsades de pointes or prolong the QT interval. Enhanced postural hypotension if used w/ other antihypertensive drugs. Concurrent use w/ other CNS depressants may cause increased CNS depression. Co-admin w/ antacids or sucralfate may decrease sulpiride absorption. Concurrent use w/ lithium increases the risk of extrapyramidal side effects. May reduce effectiveness of ropinorole.
Potentially Fatal: Reciprocal antagonism of effects between levodopa and neuroleptics.
Food Interaction
Enhanced sedative effects w/ alcohol.
Description: Sulpiride is a substituted benzamide antipsychotic which is a selective antagonist of central dopamine (D2, D3, D4) receptor.
Absorption: Slowly absorbed from the GI tract. Time to peak plasma concentration: 3-6 hr. Low bioavailability and subject to interindividual variation.
Distribution: Rapidly distributed to the tissues but passage across the blood-brain barrier is poor; distributed into breast milk. Plasma protein binding: Approx 40%.
Excretion: Excreted 95% (mainly as unchanged drug) via urine and faeces. Plasma half-life: Approx 8-9 hr.
Chemical Structure

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Sulpiride, CID=5355, (accessed on Jan. 23, 2020)

Store below 25°C
MIMS Class
ATC Classification
N05AL01 - sulpiride ; Belongs to the class of benzamides antipsychotics.
Buckingham R (ed). Sulpiride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 29/01/2015.

Dogmatil Injection. MIMS Vietnam. Accessed 30/07/2015.

Joint Formulary Committee. Sulpiride. British National Formulary [online]. London. BMJ Group and Pharmaceutical Press. Accessed 29/01/2015.

Disclaimer: This information is independently developed by MIMS based on Sulpiride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in